Our Commitment to Public Health

As a global leader in in vitro diagnostics and infectious disease management for over 55 years, bioMérieux has always been driven by an unrelenting commitment to improve public health worldwide. With expertise, partnerships, and proprietary research, bioMérieux has been standing alongside health organizations and providers to combat the spread of infectious disease, including the SARS-CoV-2 virus, which the World Health Organization declared a global pandemic on March 11, 2020.

Our Latest COVID-19 Developments

Test Updates

To help governments and healthcare professionals fight the COVID-19 pandemic and global health crisis, we can currently provide our customers with testing solutions that range from extraction to real-time PCR diagnosis. We currently have two complementary diagnostic solutions and have a third test under development. Our tests have the necessary high quality, validation, and regulatory market approvals to assure patient, physician, and lab professional confidence.

The SARS-COV-2 R-GENE® test is a real-time PCR assay produced in France and has been available as CE marked since April 10th and received Emergency Use Authorization (EUA) from the FDA on May 6, 2020. 

The BIOFIRE® RP2.1 Panel is our syndromic solution to the COVID-19 pandemic. It includes SARS-CoV-2 as well as 21 additional common respiratory pathogens. This assay received Emergency Use authorization from the FDA on May 1, 2020.

The VIDAS® SARS-COV-2 IgM and VIDAS® SARS-COV-2 IgG are automated qualitative assays for the detection of immunoglobulin M and immunoglobulin G, specific to the SARS-CoV-2 antigens in humans. This assay received Emergency Use Authorization from the FDA on August 7, 2020. Read the press release.

View our list of Comprehensive COVID-19 Solutions


Educational Resources

Use the links below to view additional resources regarding COVID-19. We will continually update this section as materials become available.

bioMérieux Connection Articles - COVID-19

COVID-19 is a highly contagious virus that is creating an urgent need for answers about how to prevent it, treat it, and care for secondary infections that may arise. Scientists are working tirelessly to confirm the virus' origin, study its genetic makeup, how it behaves, and identify what might kill it or prevent it. Learn more at bioMerieuxConnection.com.

Mass Testing vs. Targeted Testing

Sepsis & COVID-19 Relationship

Treatment Options for COVID-19

bioMérieux Connection Articles - Antimicrobial Stewardship

Antimicrobial resistance continues to pose a global threat to human health. Studies have found that some COVID-19 patients developed dangerous – and sometimes deadly – secondary bacterial co-infections, such as bacterial pneumonia and sepsis. Additionally, studies have shown the COVID-19 may have an adverse impact on antiicrobial stewardship efforts for a variety of reasons. Diagnostic considerations are a key factor in advancing antimicrobial stewardship – and helping the medical and scientific communities to gain new strength in the ongoing fight against COVID-19. Learn more at bioMerieuxConnection.com.

Telemedicine and COVID-19

Antibiotic Treatment Duration

COVID-19 and Stewardship Efforts

Virtual Learning Lounge

In addition to the development of diagnostic tests for the detection of SARS-CoV-2, we are actively collaborating and standing alongside healthcare facilities and organizations, frontline medical professionals, and advocacy groups to support the fight against all infectious diseases. Our bioMérieux Summer Learning Lounge offers consistent, on-demand selection of education to support healthcare professionals to combat the spread of infectious disease and enhance antimicrobial stewardship programs, especially in the wake of COVID-19. We will offer exclusive content and sneak peeks of virtual events to come. We are here for you, and look forward to continuing to improve public health, together.

Visit our Learning Lounge   

Pioneering Diagnostics